216 related articles for article (PubMed ID: 31697015)
1. The Potential of Probiotics in the Prevention and Treatment of Atherosclerosis.
O'Morain VL; Ramji DP
Mol Nutr Food Res; 2020 Feb; 64(4):e1900797. PubMed ID: 31697015
[TBL] [Abstract][Full Text] [Related]
2. [Changes in the intestinal microbiota as a risk factor for dyslipidemia, atherosclerosis and the role of probiotics in their prevention].
Oynotkinova OS; Nikonov EL; Demidova TY; Baranov AP; Kryukov EV; Dedov EI; Karavashkina EA
Ter Arkh; 2020 Oct; 92(9):94-101. PubMed ID: 33346437
[TBL] [Abstract][Full Text] [Related]
3. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation.
Mencarelli A; Cipriani S; Renga B; Bruno A; D'Amore C; Distrutti E; Fiorucci S
PLoS One; 2012; 7(9):e45425. PubMed ID: 23029000
[TBL] [Abstract][Full Text] [Related]
4. Probiotics Bring New Hope for Atherosclerosis Prevention and Treatment.
Zhai T; Wang P; Hu X; Zheng L
Oxid Med Cell Longev; 2022; 2022():3900835. PubMed ID: 36193065
[TBL] [Abstract][Full Text] [Related]
5. The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases.
Sanchez-Rodriguez E; Egea-Zorrilla A; Plaza-Díaz J; Aragón-Vela J; Muñoz-Quezada S; Tercedor-Sánchez L; Abadia-Molina F
Nutrients; 2020 Feb; 12(3):. PubMed ID: 32110880
[TBL] [Abstract][Full Text] [Related]
6. [Dietary therapy for prevention and treatment of atherosclerosis from the perspective of anti-inflammation].
Tada N
Nihon Rinsho; 2011 Jan; 69(1):110-8. PubMed ID: 21226270
[TBL] [Abstract][Full Text] [Related]
7. Nutraceuticals as therapeutic agents for atherosclerosis.
Moss JWE; Williams JO; Ramji DP
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1562-1572. PubMed ID: 29454074
[TBL] [Abstract][Full Text] [Related]
8. The Effects of Probiotics on Inflammation, Endothelial Dysfunction, and Atherosclerosis Progression: A Mechanistic Overview.
Mahdavi-Roshan M; Salari A; Kheirkhah J; Ghorbani Z
Heart Lung Circ; 2022 May; 31(5):e45-e71. PubMed ID: 35153150
[TBL] [Abstract][Full Text] [Related]
9. Updates in understanding the hypocholesterolemia effect of probiotics on atherosclerosis.
Hassan A; Din AU; Zhu Y; Zhang K; Li T; Wang Y; Luo Y; Wang G
Appl Microbiol Biotechnol; 2019 Aug; 103(15):5993-6006. PubMed ID: 31201452
[TBL] [Abstract][Full Text] [Related]
10. Lipid-modifying effects of nutraceuticals: An evidence-based approach.
Sahebkar A; Serban MC; Gluba-Brzózka A; Mikhailidis DP; Cicero AF; Rysz J; Banach M
Nutrition; 2016; 32(11-12):1179-92. PubMed ID: 27324061
[TBL] [Abstract][Full Text] [Related]
11. Role of Probiotics in Human Gut Microbiome-Associated Diseases.
Kim SK; Guevarra RB; Kim YT; Kwon J; Kim H; Cho JH; Kim HB; Lee JH
J Microbiol Biotechnol; 2019 Sep; 29(9):1335-1340. PubMed ID: 31434172
[TBL] [Abstract][Full Text] [Related]
12. Food and food supplements with hypocholesterolemic effects.
Deng R
Recent Pat Food Nutr Agric; 2009 Jan; 1(1):15-24. PubMed ID: 20653522
[TBL] [Abstract][Full Text] [Related]
13. [Advisability of using probiotics in the treatment of atherogenic dyslipidemia].
Zvenigorodskaia LA; Cherkashova EA; Samsonova NG; Nilova TV; Sil'verstova SIu
Eksp Klin Gastroenterol; 2011; (2):37-43. PubMed ID: 21563361
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of lipid-lowering probiotics on the atherosclerosis development.
Saadh MJ; Bazghandi B; Jamialahmdi H; Rahimzadeh-Bajgiran F; Forouzanfar F; Esmaeili SA; Saburi E
Eur J Pharmacol; 2024 May; 971():176527. PubMed ID: 38554932
[TBL] [Abstract][Full Text] [Related]
15. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.
Berman AN; Blankstein R
Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838
[TBL] [Abstract][Full Text] [Related]
16. Amelioration of TMAO through probiotics and its potential role in atherosclerosis.
Din AU; Hassan A; Zhu Y; Yin T; Gregersen H; Wang G
Appl Microbiol Biotechnol; 2019 Dec; 103(23-24):9217-9228. PubMed ID: 31655880
[TBL] [Abstract][Full Text] [Related]
17. The role of probiotics on each component of the metabolic syndrome and other cardiovascular risks.
Miglioranza Scavuzzi B; Miglioranza LH; Henrique FC; Pitelli Paroschi T; Lozovoy MA; Simão AN; Dichi I
Expert Opin Ther Targets; 2015; 19(8):1127-38. PubMed ID: 25872805
[TBL] [Abstract][Full Text] [Related]
18. Nutraceuticals for prevention of atherosclerosis: Targeting monocyte infiltration to the vascular endothelium.
Kim MJ; Jung SK
J Food Biochem; 2020 Jun; 44(6):e13200. PubMed ID: 32189369
[TBL] [Abstract][Full Text] [Related]
19. An overview of the new frontiers in the treatment of atherogenic dyslipidemias.
Rached FH; Chapman MJ; Kontush A
Clin Pharmacol Ther; 2014 Jul; 96(1):57-63. PubMed ID: 24727469
[TBL] [Abstract][Full Text] [Related]
20. Prevention of Cardiovascular Diseases with Anti-Inflammatory and Anti- Oxidant Nutraceuticals and Herbal Products: An Overview of Pre-Clinical and Clinical Studies.
Jain S; Buttar HS; Chintameneni M; Kaur G
Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):145-157. PubMed ID: 30109827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
